Patient Access | TREMFYA® (guselkumab) HCP

AFTER CONSIDERING THE EFFICACY AND SAFETY OF TREMFYA® FOR YOUR ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY

NATIONALLY, 9 OUT OF 10 COMMERCIALLY INSURED PATIENTS HAVE FIRST-LINE, PREFERRED* ACCESS TO TREMFYA®

National, Preferred, First-line Formulary Coverage for TREMFYA®

The information provided does not imply comparable safety or efficacy between products and only represents access information. Indicated trademarks are the registered trademarks of their respective owners. Please refer to each product’s Prescribing Information for indication(s), recommended dosing, and administration.

IL=interleukin.

*“Preferred” means TREMFYA® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class.

“Best-in-class” means the number of first-line covered lives is greater for TREMFYA® than for other products in the IL-23 inhibitor class (Skyrizi® [risankizumab-rzaa], Ilumya® [tildrakizumab-asmn]).

“Superior” means the number of first-line covered lives is at least 10% greater for TREMFYA® than for products in the IL-17 inhibitor class (Cosentyx® [secukinumab], Taltz® [ixekizumab], Siliq® [brodalumab]).

Collected in November 2021 and is subject to change. This information does not provide advice or guarantee coverage or payment. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply. This may not represent 100% of formulary lives due to data limitations.

Source: Managed Markets Insight and Technology, LLC™, a trademark of MMIT, as of November 2021.

Visit TremfyaBioCoordiNATION.com to access the Commercial Formulary Coverage tool to look up preferred first-line access to TREMFYA® for your local area.